BAL PHARMA LTD. (BALPHARMA) financials

BAL PHARMA LTD. (BALPHARMA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Market Cap: ₹152Cr.
Current Price: ₹95.8
Stock P/E: 20.1
ROE: 6.59%
ROCE: 9.30%
Book Value: ₹65.4
Dividend Yield: 1.25%
52W High / Low: ₹125/59.7

In Jun 2026, BAL PHARMA LTD. (BALPHARMA) reported sales ₹88.43 Cr and net profit ₹1.16 Cr.

Annual TTM: sales ₹334 Cr, net profit ₹8 Cr.

Shareholding: Promoters 50.87% (Sep 2026), FIIs 0.28% (Sep 2026), Public 48.87% (Sep 2026), No. of Shareholders 15,241% (Sep 2026).

BALPHARMA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	74.70	72.89	81.78	65.64	73.75	87.49	83.92	88.43
Expenses	67.23	64.96	73.95	59.49	67.97	77.82	73.29	80.48
Operating Profit	7.47	7.93	7.83	6.15	5.78	9.67	10.63	7.95
OPM %	10.00%	10.88%	9.57%	9.37%	7.84%	11.05%	12.67%	8.99%
Other Income	0.35	0.51	0.99	0.74	1.13	0.35	-0.22	0.46
Interest	4.18	5.02	3.94	4.05	3.86	4.85	4.05	4.47
Depreciation	2.12	2.68	2.07	2.52	2.27	3.23	3.04	2.78
Profit before tax	1.52	0.74	2.81	0.32	0.78	1.94	3.32	1.16
Tax %	21.05%	5.41%	-99.29%	0.00%	0.00%	0.00%	-11.75%	0.00%
Net Profit	1.20	0.69	5.61	0.32	0.78	1.95	3.70	1.16
EPS in Rs	0.75	0.43	3.52	0.20	0.49	1.22	2.32	0.73
Raw PDF	—	—	—	—	—	—	—	—

BALPHARMA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	171	249	280	303	339	302	311	334
Expenses	164	223	257	277	307	272	278	300
Operating Profit	7	27	23	26	32	30	32	34
OPM %	4.1%	11%	8%	9%	9%	10%	10%	10%
Other Income	4	3	6	2	2	2	2	2
Interest	13	12	11	13	15	17	17	17
Depreciation	7	7	7	7	10	10	11	11
Profit before tax	-9	10	12	9	9	6	6	7
Tax %	-2%	7%	29%	28%	17%	-36%	-6%	—
Net Profit	-9	9	9	6	8	8	7	8
EPS in Rs	-6.28	6.14	5.79	3.91	4.89	4.90	4.24	4.76
Dividend Payout %	0%	16%	17%	26%	25%	24%	28%	—

BALPHARMA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	14	14	15	15	16	16	16	16
Reserves	63	52	64	72	80	77	83	88
Borrowings	104	99	104	98	125	134	145	154
Other Liabilities	76	74	78	104	126	108	107	133
Total Liabilities	257	239	262	290	348	334	351	391
Fixed Assets	57	56	53	53	63	79	87	94
CWIP	0	0	0	1	0	0	3	7
Investments	7	7	8	8	8	9	5	4
Other Assets	193	176	200	227	276	245	256	285
Total Assets	257	239	262	290	348	334	351	391

BALPHARMA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	12	22	10	31	5	29	20	31
Cash from Investing Activity	-12	-3	-7	-13	-22	-19	-15	-21
Cash from Financing Activity	0	-20	-3	-17	17	-7	-8	-10
Net Cash Flow	-0	-2	0	-0	0	3	-2	1
Free Cash Flow	7	18	7	23	-9	18	5	9
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	68%	312%	39%	135%	22%	104%	74%	95%

BALPHARMA shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	50.87%	50.87%	50.87%	50.87%	50.87%	50.87%	50.87%	50.87%
FIIs	0.14%	0.14%	0.15%	0.23%	0.14%	0.14%	0.15%	0.28%
Public	49.00%	49.01%	48.99%	48.91%	49.01%	49.01%	48.99%	48.87%
No. of Shareholders	15,667	15,723	15,826	15,774	15,520	15,214	14,974	15,241

BALPHARMA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	107	110	102	101	114	110	114	113
Inventory Days	217	291	146	162	210	167	238	269
Days Payable	148	170	118	158	195	148	189	206
Cash Conversion Cycle	176	232	130	105	129	129	163	176
Working Capital Days	68	55	62	61	61	32	29	27
ROCE %	10%	2%	13%	12%	10%	11%	10%	9%

BALPHARMAUpdated 18 Oct 2026, 17:07

Bal Pharma Ltd.

BALPHARMAUpdated 18 Oct 2026, 17:07

Market Cap

₹152Cr.

Current Price

₹95.8

High / Low

₹125/59.7

Stock P/E

20.1

ROE6.59%

ROCE9.30%

Book Value₹65.4

Face Value₹10.0

Dividend Yield1.25%

About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	70.17	3.64	63.33	0.45	2.12	1.53	22.22	1.2	0.76
Sep 2023	92.3	3.82	84.64	0.41	2.02	2.23	28.25	1.6	1.02
Dec 2023	81.49	3.86	73.67	0.26	2.55	1.67	25.15	1.26	0.8
Mar 2024	94.58	3.34	85.4	1.85	2.14	5.55	3.78	5.34	3.38
Jun 2024	73.13	3.71	66.57	0.29	2.43	0.71	50.7	0.36	0.23
Sep 2024	74.7	4.18	67.23	0.35	2.12	1.52	21.05	1.2	0.75
Dec 2024	72.89	5.02	64.96	0.51	2.68	0.74	5.41	0.69	0.43
Mar 2025	81.78	3.94	73.95	0.99	2.07	2.81	-99.29	5.61	3.52
Jun 2025	65.64	4.05	59.49	0.74	2.52	0.32	0	0.32	0.2
Sep 2025	73.75	3.86	67.97	1.13	2.27	0.78	0	0.78	0.49
Dec 2025	87.49	4.85	77.82	0.35	3.23	1.94	0	1.95	1.22
Mar 2026	83.92	4.05	73.29	-0.22	3.04	3.32	-11.75	3.7	2.32
Jun 2026	88.43	4.47	80.48	0.46	2.78	1.16	0	1.16	0.73

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	187	7	170	1	7	5	23	4	3.12
Mar 2016	198	6	181	2	7	5	46	3	2.18
Mar 2017	226	8	206	3	6	9	38	5	3.75
Mar 2018	210	9	187	2	7	8	30	6	4.19
Mar 2019	223	13	203	3	6	4	-53	7	4.77
Mar 2020	171	13	164	4	7	-9	-2	-9	-6.28
Mar 2021	249	12	223	3	7	10	7	9	6.14
Mar 2022	280	11	257	6	7	12	29	9	5.79
Mar 2023	303	13	277	2	7	9	28	6	3.91
Mar 2024	339	15	307	2	10	9	17	8	4.89
Mar 2025	302	17	272	2	10	6	-36	8	4.9
Mar 2026	311	17	278	2	11	6	-6	7	4.24
TTM	334	17	300	2	11	7	—	8	4.76

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	50.87%
FIIs	0.28%
Public	48.87%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	51.24%	0.13%	—	48.64%
Mar 2024	51.24%	0.13%	—	48.64%
Jun 2024	51.24%	0.13%	—	48.63%
Sep 2024	50.87%	0.13%	—	49.01%
Dec 2024	50.87%	0.14%	—	49%
Mar 2025	50.87%	0.14%	—	49.01%
Jun 2025	50.87%	0.15%	—	48.99%
Sep 2025	50.87%	0.23%	—	48.91%
Dec 2025	50.87%	0.14%	—	49.01%
Mar 2026	50.87%	0.14%	—	49.01%
Jun 2026	50.87%	0.15%	—	48.99%
Sep 2026	50.87%	0.28%	—	48.87%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	13	43	49	59	164	52	1	1	110	164
Mar 2016	13	44	70	67	193	56	4	1	132	193
Mar 2017	14	52	74	78	219	60	2	0	157	219
Mar 2018	14	58	91	88	251	58	0	7	185	251
Mar 2019	14	63	104	76	257	57	0	7	193	257
Mar 2020	14	52	99	74	239	56	0	7	176	239
Mar 2021	15	64	104	78	262	53	0	8	200	262
Mar 2022	15	72	98	104	290	53	1	8	227	290
Mar 2023	16	80	125	126	348	63	0	8	276	348
Mar 2024	16	77	134	108	334	79	0	9	245	334
Mar 2025	16	83	145	107	351	87	3	5	256	351
Mar 2026	16	88	154	133	391	94	7	4	285	391

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	14	-6	-7	2
Mar 2016	1	-14	12	0
Mar 2017	6	-8	2	0
Mar 2018	13	-16	4	1
Mar 2019	12	-12	0	0
Mar 2020	22	-3	-20	-2
Mar 2021	10	-7	-3	0
Mar 2022	31	-13	-17	0
Mar 2023	5	-22	17	0
Mar 2024	29	-19	-7	3
Mar 2025	20	-15	-8	-2
Mar 2026	31	-21	-10	1

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	88	105	99	111	107	110	102	101	114	110	114	113
Inventory Days	132	145	171	240	217	291	146	162	210	167	238	269
Days Payable	142	163	168	183	148	170	118	158	195	148	189	206
Cash Conversion Cycle	78	87	101	168	176	232	130	105	129	129	163	176
Working Capital Days	15	17	38	77	68	55	62	61	61	32	29	27
ROCE %	11%	10%	13%	12%	10%	2%	13%	12%	10%	11%	10%	9%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BAL PHARMA LTD. (BALPHARMA)?

The reported market capitalisation for BAL PHARMA LTD. (BALPHARMA) is ₹152Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BALPHARMA?

The current price shown for BAL PHARMA LTD. (BALPHARMA) on Fincrux is ₹95.8 with a 52-week high/low of ₹125/59.7.

What is the P/E ratio of BAL PHARMA LTD. (BALPHARMA)?

The stock P/E for BAL PHARMA LTD. (BALPHARMA) is 20.1 on Fincrux, with ROE at 6.59% and ROCE at 9.30%.

What were BALPHARMA latest quarterly results?

For Jun 2026, BAL PHARMA LTD. (BALPHARMA) reported sales ₹88.43 Cr and net profit ₹1.16 Cr (figures in ₹ crore unless noted).

What are BALPHARMA annual sales and net profit?

For TTM, BAL PHARMA LTD. (BALPHARMA) shows sales of ₹334 Cr and net profit of ₹8 Cr on the Fincrux profit & loss statement.

Who owns BAL PHARMA LTD. (BALPHARMA)?

Latest shareholding for BAL PHARMA LTD. (BALPHARMA) on Fincrux: Promoters 50.87% (Sep 2026), FIIs 0.28% (Sep 2026), Public 48.87% (Sep 2026), No. of Shareholders 15,241% (Sep 2026).

Where can I find BAL PHARMA LTD. (BALPHARMA) financials?

BAL PHARMA LTD. (BALPHARMA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BALPHARMA balance sheet and cash flow?

Yes. The BAL PHARMA LTD. (BALPHARMA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 17:07